Sham Mailankody, MBBS, on Further Research With ALLO-715

Video

The associate attending physician at Memorial Sloan Kettering Cancer Center discussed further research that remains to be conducted with the allogeneic cell therapy.

“Can we understand why some patients have a long response and others don't? Can we understand the importance of antigen BCMA expression at baseline and at the time of relapse, and correlations with how high the CAR T expands? How long do the cells persist? Some of this is data that we're currently trying to generate to try and better understand how we can get more patients with these2+year responses.”

ALLO-715 (Allogene), an allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, had a manageable safety profile with promising efficacy in patients with relapsed/refractory multiple myeloma (R/R MM) in the phase 1 UNIVERSAL open-label trial (NCT04093596). These data, which includedan objective response rate of 65% and a very good partial response rate of about 50%, were presented by Sham Mailankody, MBBS, associate attending physician, Memorial Sloan Kettering Cancer Center, 64th American Society of Hematology (ASH) Annual Meeting, held December 10-12, 2022, in New Orleans, Louisiana.

CGTLive spoke with Mailankody to learn more about ALLO-715 and research that remains to be done and questions that remain to be answered with the therapy and with cell therapy for R/R MM in general. He also discussed advantages of allogeneic therapies over autologous therapies.

REFERENCE
2019 Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. Presented at: 64th ASH Annual Meeting, December 10-12, 2022, in New Orleans, Louisiana. Abstract #2019.
Related Videos
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
© 2024 MJH Life Sciences

All rights reserved.